A Call To Action: Developing an Agile Global Regulatory Affairs Workforce for the Future

As leaders of biopharmaceutical regulatory affairs organizations, we must learn from the past, thrive in the present and strive for an even better future. We understand the strategic role regulatory affairs professionals play in biopharmaceutical companies, one that uniquely spans the entire continuum of drug development. Our professionals must navigate the increasingly complex regulatory environment, strengthening company engagement with global regulators and other stakeholders to successfully deliver innovative products to patients. Our organizations are only as strong as the people on our teams. As the future of therapeutic development changes in response to technological and scientific advances, we have an obligation to develop, recruit and retain top talent, and build a competency framework to not only meet today’s demands, but to better equip the workforce of the future to improve patients’ access to treatments. There is a great opportunity before us–upskilling our current professionals, attracting individuals with a diversity of expertise into the profession, and setting up the next generation for dynamic and successful careers. This is a call to action for professional societies, academic organizations, regulators, biopharmaceutical companies, and other interested stakeholders to prepare and develop the Global Regulatory Affairs workforce of the future.

Authors

Institutions

Publication Details

Journal
Therapeutic Innovation & Regulatory Science
Published
2025-12-05
DOI
https://doi.org/10.1007/s43441-025-00877-w
Primary Topic
Biomedical Ethics and Regulation
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Call To Action: Developing an Agile Global Regulatory Affairs Workforce for the Future

Elizabeth P. Reilly, Max Wegner, Sean Curtis, Michael R. Garvin et al.
Therapeutic Innovation & Regulatory Science
Biomedical Ethics and Regulation
article

A Call To Action: Developing an Agile Global Regulatory Affairs Workforce for the Future

Elizabeth P. Reilly, Max Wegner, Sean Curtis, Michael R. Garvin, Nawar Latif, David C. Isom, Kathy Williams, Donna Boyce, Kevin Carl, Fabio Bisordi, Michelle Rohrer, Amy Bertha, Lina Aljuburi, Mark Taisey, Katrin Rupalla, Jennifer Dudinak, Carlos Garner, Sabine Luik, Raymond C. Votzmeyer, Nicole Mahoney, Virginia Beakes-Read
article en

Abstract

As leaders of biopharmaceutical regulatory affairs organizations, we must learn from the past, thrive in the present and strive for an even better future. We understand the strategic role regulatory affairs professionals play in biopharmaceutical companies, one that uniquely spans the entire continuum of drug development. Our professionals must navigate the increasingly complex regulatory environment, strengthening company engagement with global regulators and other stakeholders to successfully deliver innovative products to patients. Our organizations are only as strong as the people on our teams. As the future of therapeutic development changes in response to technological and scientific advances, we have an obligation to develop, recruit and retain top talent, and build a competency framework to not only meet today’s demands, but to better equip the workforce of the future to improve patients’ access to treatments. There is a great opportunity before us–upskilling our current professionals, attracting individuals with a diversity of expertise into the profession, and setting up the next generation for dynamic and successful careers. This is a call to action for professional societies, academic organizations, regulators, biopharmaceutical companies, and other interested stakeholders to prepare and develop the Global Regulatory Affairs workforce of the future.

Therapeutic Innovation & Regulatory ScienceVol. 60(2)
AstraZeneca (United Kingdom) (GB), Roche (Switzerland) (CH), Novartis (Switzerland) (CH), Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Amgen (United States) (US), Johnson & Johnson (United States) (US), Bristol-Myers Squibb (Germany) (DE), Eli Lilly (United States) (US), Pfizer (United States) (US), AbbVie (United States) (US), Sanofi (France) (FR), Bristol-Myers Squibb (Sweden) (SE), Takeda (United States) (US), GlaxoSmithKline (Germany) (DE), AstraZeneca (United States) (US), Bayer (Germany) (DE)
Openalex Percentile: Top 52%
Biomedical Ethics and Regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.